444324-92-9

Upstream product

• 444326-43-6 6-chloro-2-trifluoromethyl-7-(2,4,6-trimethyl-phenyl)-7H-imidazo[1,2-a]imidazole-3-carboxylic acid ethyl ester 
• 26389-60-6 N-(n-propyl)-N-(cyclopropanemethyl)amine 
• 75-24-1 trimethylaluminum 

Downstream Products

• 444324-93-0 [6-Chloro-2-trifluoromethyl-7-(2,4,6-trimethyl-phenyl)-7H-imidazo [1,2-a]imidazol-3-ylmethyl]-cyclopropylmethyl-propyl-amine 

Relevant academic research and scientific papers

Discovery of 6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3- ylmethylamines, a novel class of corticotropin-releasing factor receptor type 1 (CRF1R) antagonists

A novel series of [6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a] imidazol-3-ylmethyl]-dialkylamines was discovered as potent CRF1R antagonists. The optimization of binding affinity in the series by the parallel reaction approach is discus

Imidazolyl derivatives as corticotropin releasing factor inhibitors

The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.